查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球核子医学市场评估：按类型、应用、最终用户、地区、机会、预测（2017-2031）
市场调查报告书
商品编码
1402438

全球核子医学市场评估：按类型、应用、最终用户、地区、机会、预测（2017-2031）

Nuclear Medicine Market Assessment, By Type, By Application, By End-users, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 220 Pages | 商品交期: 3-5个工作天内

价格

全球核子医学市场规模预计到2023年将达到101亿美元，到2031年将达到253.8亿美元，2024-2031年预测期间复合年增长率为12.21%。由于强大的市场参与者和强大的技术实力，该市场充满活力且前景广阔。由于慢性病的流行和技术进步等因素促进了市场的成长，该市场正在成长。

据世界卫生组织称，心血管疾病、中风、癌症和糖尿病是全世界死亡的主要原因。这些疾病导致的死亡率上升预计将推动全球核医学的发展。放射性药物领域的技术进步为癌症和神经系统疾病等标靶疾病开发新的治疗方案，正在推动核医市场的成长。有利的政府政策正在促进全球核子医学市场的成长。然而，高资本投资、监管合规、供应链中断和缺乏熟练专业人员等障碍可能会影响市场成长。

目标疾病盛行率

标靶疾病的流行是核医市场的关键驱动因素。癌症和心血管疾病等慢性病的发生率和盛行率不断增加，推动了对核子医学手术的需求。核子医学在这些疾病的诊断和治疗中发挥重要作用，导致对先进诊断和治疗方案的需求增加。核子医学技术能够识别特定疾病标记并预测个体对治疗的反应，这正在推动其采用并进一步促进市场扩张。2021年，2,050万人将死于心血管疾病，1,000万人死于癌症，670万人死于糖尿病。

技术进步

快速的技术进步正在推动全球核子医学市场。诊断影像、改进的治疗技术以及快速准确的治疗计划诊断的重大进步正在推动核医市场的发展。此外，放射性示踪剂和放射性同位素生产的进步使得开发更有针对性和更有效的核医治疗成为可能。人工智慧和机器学习 (ML) 在核医学中的整合正在推动该领域的重大进步。

人工智慧，包括机器学习、深度学习、人工神经网路和卷积神经网络，在核医成像精准医疗的发展中发挥重要作用。这些技术使医学影像工作流程自动化，并应用于核医中典型医学影像工作流程的所有阶段，包括规划、影像撷取和解释。

增加政府在研发方面的措施和资金

增加对核医学开发和製造的投资透过促进成长和扩张对市场产生积极影响。多个投资者正在为核子医学研发和创新提供大量资金。增加资金和投资在推动核医学技术和扩大其诊断和治疗应用方面发挥关键作用，从而导致市场显着增长。

北美主导全球核医学市场

北美将在2022年成为市场领导者，预计将继续快速发展。强大的医疗基础设施、大量的核子医学手术以及巨额的研发投资造就了该地区庞大的市场份额。

COVID-19 的影响

COVID-19大流行对核医市场产生了重大影响。由于院内感染，对 COVID-19 患者的优先治疗以及医院活动的关闭导致核医学手术和收入下降。核子医学研究领域和放射性製药产业受到疫情的不利影响，导致癌症筛检数量大幅下降。大流行扰乱了放射性药物供应链。2021年，由于病患数量的增加以及医院和其他医疗设施医疗程序的恢復，市场公司的收入逐渐增加。疫情为核医市场带来重大挑战，产业需要适应新常态并实施减轻影响的策略。

本报告研究和分析了全球核子医学市场，提供市场规模和预测、市场动态以及主要参与者的现状和前景。

目录

第一章研究方法论

第二章 专案范围与定义

第三章 COVID-19对全球核子医学市场的影响

第 4 章执行摘要

第五章 全球核子医学市场展望（2017-2031）

  • 市场规模及预测
    • 金钱数额
    • 数量
  • 按类型
    • 诊断核子医学
    • 治疗性核子医学
  • 按用途
  • 按最终用户
  • 按地区
  • 市场占有率：依公司划分（2023 年）
  • 北美
    • 市场规模及预测
    • 按类型
    • 按用途
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第六章 市场测绘（2023）

  • 按类型
  • 按用途
  • 按最终用户
  • 按地区

第七章 宏观环境与产业结构

  • 供需分析
  • 进出口分析 - 数量和价值
  • 供应/价值链分析
  • PESTEL 分析
  • 波特五力分析

第八章市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第九章 监理架构与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/新技术

第十章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT分析（5家进入市场的公司）
  • 专利分析（如果适用）

第11章价格分析

第十二章案例研究

第十三章 主要公司展望

  • GE Healthcare
  • Cardinal Health
  • Jubilant Life Sciences Ltd
  • Curium Pharma
  • Nordion Inc.
  • Bracco Imaging S.P.A
  • NTP Radioisotopes SOC Ltd.
  • EczacIbasI-Monrol Nuclear Products
  • Lantheus Medical Imaging Inc
  • Eckert & Ziegler
  • Mallinckrodt

第十四章 战略建议

第十五章 关于我们公司、免责声明

Product Code: MX10819

Global nuclear medicine market size was valued at USD 10.1 billion in 2023, which is expected to reach USD 25.38 billion in 2031, with a CAGR of 12.21% for the forecast period between 2024 and 2031F. The global nuclear medicine market is highly dynamic and promising, with the presence of strong market players and robust technologies. The global nuclear medicine market is experiencing growth due to factors such as increasing prevalence of chronic diseases and technological advancements that are contributing towards growth of the market.

According to WHO, cardiovascular diseases, stroke, cancer, and diabetes are among the leading causes of death globally. Increasing mortality rates due to these diseases are expected to drive the global nuclear medicine. Technological advancements in the field of radiopharmaceuticals for the development of new treatment options for targeted conditions such as cancer and neurological disorders are promoting growth in the nuclear medicine market. Favorable government policies are contributing towards the growth of the global nuclear medicine market. However, hindrances such as high capital investment, regulatory compliance, supply chain disruptions and lack of skilled professionals can impact the growth of the market.

In August 2023, NorthStar Medical Radioisotopes, LLC, and Curadh MTR Inc. (Curadh) announced a strategic long-term supply agreement for the therapeutic radioisotope non-carrier added actinium-225 (Ac-225). Under this agreement, NorthStar will provide radioisotope non-carrier added actinium-225 (Ac-225) to Curadh for the development of treatment of lethal tumors.

Growing Prevalence of Targeted Conditions

The growing prevalence of targeted conditions is a significant driver of the nuclear medicine market. The increasing incidence and prevalence of cancer, cardiovascular diseases, and other chronic ailments are fueling the demand for nuclear medicine procedures. Nuclear medicine plays a substantial role in the diagnosis and treatment of these diseases, leading to a rising demand for advanced diagnostic and therapeutic options. The ability of nuclear medicine techniques to identify specific disease markers and predict individual responses for treatment is driving their adoption, further contributing to market expansion. Cardiovascular deaths accounted for 20.5 million deaths, cancer accounted for 10 million deaths and diabetes accounting for 6.7 million deaths in 2021.

Technological Advancements

Rapid technological advancements are driving the market for global nuclear medicine. Key advancements, such as improved imaging and therapeutic techniques and faster and accurate diagnosis for treatment planning are driving the market for nuclear medicine. Additionally, advancements in radiotracers and radioisotope production have enabled the development of more targeted and effective nuclear medicine treatments. The integration of artificial intelligence (AI) and machine learning (ML) in nuclear medicine is driving significant advancements in the field.

AI, including ML, deep learning, artificial neural networks, and convolutional neural networks, is playing a crucial role in developing precision medicine in nuclear medicine imaging. These technologies are automating the workflow of medical imaging and are being applied to all phases of a typical medical imaging workflow in nuclear medicine, including planning, image acquisition, and interpretation. In June 2023, Siemens Healthineers announced the launch of FDA-approved POSLUMA (flotufolastat F 18) injection to be used as PET imaging agent. The injection is manufactured and distributed by PETNET Solution. Siemens Healthineers launched its product at SNMMI 2023 annual meeting (Society of Nuclear Medicine and Molecular Imaging).

Increasing Funding in Government Initiatives and Research and Development

Increasing investment in nuclear medicine development and manufacturing is positively impacting the market by driving growth and expansion. Several investors are providing huge amount of funds for doing research and development and innovation in nuclear medicines. Government initiatives and funding for the development of new techniques, such as USD 70,000 funding received by Charles Sturt University to develop and offer a new micro credential course in nuclear medicine. Increasing funding and investments are playing a pivotal role in advancing nuclear medicine technologies and expanding their applications in diagnosis and treatment, leading to substantial market growth. In July 2022, Framatome announced buying minor stakes in Global Morpho Pharma. With this investment, Framatome aims to expand its assistance for the supply chain of Lutetium-177 and other prospective isotopes for therapeutic uses and improve its operations supporting the development of nuclear medicine.

North America Dominates the Global Nuclear Medicine Market

North America was the market leader in 2022 and is expected to continue to develop rapidly in the coming years. Strong healthcare infrastructure, a high volume of nuclear medicine procedures, and huge investment in research and development contribute to the region's significant market share.

In 2021, GE Healthcare & NorthStar Medical Radioisotopes signed a manufacturing and distribution agreement in the United States. The pharmaceutical diagnostics division of GE Healthcare will use a brand-new, cutting-edge production system at its Arlington Heights facility to manufacture and supply NorthStar with I-123 capsules under the NorthStar label.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the nuclear medicine market. The prioritization of COVID-19 patients and closure of hospital activities due to hospital-acquired infections led to a reduction in procedure volume and revenue in nuclear medicine. The field of nuclear medicine research and the radiopharmaceutical industry were adversely affected by the pandemic, with a significant reduction in procedure volumes for cancer screening. The pandemic hindered the supply chain of radiopharmaceuticals. Revenue for market players increased gradually in 2021, due to rise in patient volumes and the restoration of medical procedures in hospitals and other healthcare facilities. The pandemic posed significant challenges to the nuclear medicine market, requiring the industry to adapt to the new normal and implement strategies to mitigate the impact.

Key Players Landscape and Outlook

Market players are expanding their product offerings and giving patients access to a wider range of innovative technologies. Companies are expanding the range of products and services they offer to gain market share. Industry participants use a variety of growth strategies such as collaborations, mergers and acquisitions, and go-to-market strategies.

In October 2023, Cyclopharm announced that USFDA approval of its nuclear medicine called Technegas which is used for the diagnosis and management of pulmonary embolism. Technegas has already been used in more than 64 countries serving 4.7 million patients.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Nuclear Medicine Market

4. Executive Summary

5. Global Nuclear Medicine Market Outlook, 2017-2031F

  • 5.1 Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Type
    • 5.2.1 Diagnostic Nuclear Medicine
      • 5.2.1.1. PET Radiopharmaceuticals
      • 5.2.1.1.1. FDG-PET/18F
      • 5.2.1.1.2. ¬68Ga
      • 5.2.1.1.3. ¬68Cu
      • 5.2.1.1.4. ¬11Ga
      • 5.2.1.1.5. Others
      • 5.2.1.2. SPECT Radiopharmaceuticals
      • 5.2.1.2.1. Technetium-99m
      • 5.2.1.2.2. Iodine-123
      • 5.2.1.2.3. Xenon-133
      • 5.2.1.2.4. Thalium-201
      • 5.2.1.2.5. Others
    • 5.2.2. Therapeutic Nuclear Medicine
      • 5.2.2.1. Alpha Emitters
      • 5.2.2.2. Beta Emitters
      • 5.2.2.3. Brachytherapy Isotopes
    • 5.2.3. By Applications
      • 5.2.3.1. Neurology
      • 5.2.3.2. Cardiology
      • 5.2.3.3. Oncology
      • 5.2.3.4. Thyroid
      • 5.2.3.5. Bone Scans
      • 5.2.3.6. Others
    • 5.2.4. By End-users
      • 5.2.4.1. Hospitals
      • 5.2.4.2. Diagnostics Centers
      • 5.2.4.3. Others
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East & Africa
  • 5.3. By Company Market Share (%), 2023
  • 5.4. North America*
    • 5.4.1. Market Size & Forecast
      • 5.4.1.1. By Value
      • 5.4.1.2. By Volume
    • 5.4.2. By Type
      • 5.4.2.1. Diagnostic Nuclear Medicine
      • 5.4.2.1.1. PET Radiopharmaceuticals
      • 5.4.2.1.1.1. FDG-PET/18F
      • 5.4.2.1.1.2. ¬68Ga
      • 5.4.2.1.1.3. ¬68Cu
      • 5.4.2.1.1.4. ¬11Ga
      • 5.4.2.1.1.5. Others
      • 5.4.2.1.2. SPECT Radiopharmaceuticals
      • 5.4.2.1.2.1. Technetium-99m
      • 5.4.2.1.2.2. Iodine-123
      • 5.4.2.1.2.3. Xenon-133
      • 5.4.2.1.2.4. Thalium-201
      • 5.4.2.1.2.5. Others
      • 5.4.2.2. Therapeutic Nuclear Medicine
      • 5.4.2.2.1. Alpha Emitters
      • 5.4.2.2.2. Beta Emitters
      • 5.4.2.2.3. Brachytherapy Isotopes
    • 5.4.3. By Applications
      • 5.4.3.1. Neurology
      • 5.4.3.2. Cardiology
      • 5.4.3.3. Oncology
      • 5.4.3.4. Thyroid
      • 5.4.3.5. Bone Scans
      • 5.4.3.6. Others
    • 5.4.4. By End-users
      • 5.4.4.1. Hospitals
      • 5.4.4.2. Diagnostics Centers
      • 5.4.4.3. Others
    • 5.4.5. United States*
      • 5.4.5.1. By Type
      • 5.4.5.1.1. Diagnostic Nuclear Medicine
      • 5.4.5.1.1.1. PET Radiopharmaceuticals
      • 5.4.5.1.1.1.1. FDG-PET/18F
      • 5.4.5.1.1.1.2. ¬68Ga
      • 5.4.5.1.1.1.3. ¬68Cu
      • 5.4.5.1.1.1.4. ¬11Ga
      • 5.4.5.1.1.1.5. Others
      • 5.4.5.1.1.2. SPECT Radiopharmaceuticals
      • 5.4.5.1.1.2.1. Technetium-99m
      • 5.4.5.1.1.2.2. Iodine-123
      • 5.4.5.1.1.2.3. Xenon-133
      • 5.4.5.1.1.2.4. Thalium-201
      • 5.4.5.1.1.2.5. Others
      • 5.4.5.1.2. Therapeutic Nuclear Medicine
      • 5.4.5.1.2.1. Alpha Emitters
      • 5.4.5.1.2.2. Beta Emitters
      • 5.4.5.1.2.3. Brachytherapy Isotopes
      • 5.4.5.2. By Applications
      • 5.4.5.2.1. Neurology
      • 5.4.5.2.2. Cardiology
      • 5.4.5.2.3. Oncology
      • 5.4.5.2.4. Thyroid
      • 5.4.5.2.5. Bone Scans
      • 5.4.5.2.6. Others
      • 5.4.5.3. By End-users
      • 5.4.5.3.1. Hospitals
      • 5.4.5.3.2. Diagnostics Centers
      • 5.4.5.3.3. Others
    • 5.4.6. Canada
    • 5.4.7. Mexico

All segments will be provided for all regions and countries covered:

  • 5.5. Europe
    • 5.5.1. Germany
    • 5.5.2. France
    • 5.5.3. Italy
    • 5.5.4. United Kingdom
    • 5.5.5. Russia
    • 5.5.6. Netherlands
    • 5.5.7. Spain
    • 5.5.8. Turkey
    • 5.5.9. Poland
  • 5.6. South America
    • 5.6.1. Brazil
    • 5.6.2. Argentina
  • 5.7. Asia-Pacific
    • 5.7.1. India
    • 5.7.2. China
    • 5.7.3. Japan
    • 5.7.4. Australia
    • 5.7.5. Vietnam
    • 5.7.6. South Korea
    • 5.7.7. Indonesia
    • 5.7.8. Philippines
  • 5.8. Middle East & Africa
    • 5.8.1. Saudi Arabia
    • 5.8.2. UAE
    • 5.8.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Application
  • 6.3. By End-users
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis - Volume and Value
  • 7.3. Supply/Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges, Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. GE Healthcare
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Cardinal Health
  • 13.3. Jubilant Life Sciences Ltd
  • 13.4. Curium Pharma
  • 13.5. Nordion Inc.
  • 13.6. Bracco Imaging S.P.A
  • 13.7. NTP Radioisotopes SOC Ltd.
  • 13.8. EczacIbasI-Monrol Nuclear Products
  • 13.9. Lantheus Medical Imaging Inc
  • 13.10. Eckert & Ziegler
  • 13.11. Mallinckrodt

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 5. Global Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 6. Global Nuclear Medicine Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 10. North America Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 11. North America Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 12. North America Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 16. United States Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 17. United States Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 18. Canada Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 21. Canada Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 22. Canada Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 23. Mexico Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 26. Mexico Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 27. Mexico Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 28. Europe Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 31. Europe Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 32. Europe Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 33. Europe Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 37. Germany Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 38. Germany Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 39. France Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 42. France Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 43. France Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 44. Italy Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 47. Italy Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 48. Italy Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 49. United Kingdom Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 52. United Kingdom Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 53. United Kingdom Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 54. Russia Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 57. Russia Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 58. Russia Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 59. Netherlands Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 62. Netherlands Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 63. Netherlands Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 64. Spain Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 67. Spain Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 68. Spain Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 69. Turkey Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 72. Turkey Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 73. Turkey Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 74. Poland Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 77. Poland Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 78. Poland Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 79. South America Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 82. South America Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 83. South America Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 84. South America Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 88. Brazil Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 89. Brazil Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 90. Argentina Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 93. Argentina Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 94. Argentina Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 95. Asia-Pacific Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 98. Asia-Pacific Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 99. Asia-Pacific Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 100. Asia-Pacific Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 101. India Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 104. India Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 105. India Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 106. China Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 109. China Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 110. China Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 111. Japan Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 114. Japan Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 115. Japan Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 116. Australia Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 119. Australia Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 120. Australia Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 121. Vietnam Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 124. Vietnam Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 125. Vietnam Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 126. South Korea Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 129. South Korea Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 130. South Korea Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 131. Indonesia Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 134. Indonesia Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 135. Indonesia Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 136. Philippines Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 139. Philippines Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 140. Philippines Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 141. Middle East & Africa Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 144. Middle East & Africa Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 145. Middle East & Africa Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 146. Middle East & Africa Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 150. Saudi Arabia Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 151. Saudi Arabia Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 152. UAE Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 155. UAE Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 156. UAE Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 157. South Africa Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 160. South Africa Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 161. South Africa Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 162. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Applications Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023